Rbbp4 loss disrupts neural progenitor cell cycle regulation independent of Rb and leads to Tp53 acetylation and apoptosis

Autor: Laura E. Schultz‐Rogers, Michelle L. Thayer, Sekhar Kambakam, Wesley A. Wierson, Jordan A. Helmer, Mark D. Wishman, Kristen A. Wall, Jessica L. Greig, Jaimie L. Forsman, Kavya Puchhalapalli, Siddharth Nair, Trevor J. Weiss, Jon M. Luiken, Patrick R. Blackburn, Stephen C. Ekker, Marcel Kool, Maura McGrail

Publikováno v: Developmental Dynamics. 251:1267-1290

Retinoblastoma binding protein 4 (Rbbp4) is a component of transcription regulatory complexes that control cell cycle gene expression. Previous work indicated that Rbbp4 cooperates with the Rb tumor suppressor to block cell cycle entry. Here, we use

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::914497a99fae0f1b87a9d128367c08bc
https://doi.org/10.1002/dvdy.467

Author response for 'Metformin and carotid intima media thickness in never smokers with type 1 diabetes: the REMOVAL trial'

Autor: null JG Timmons, null N Greenlaw, null JG Boyle, null N Chaturvedi, null I Ford, null MCGJ Brouwers, null T Tillin, null I Hramiak, null AD Hughes, null AJ Jenkins, null BEK Klein, null R Klein, null TC Ooi, null P Rossing, null CDA Stehouwer, null N Sattar, null HM Colhoun, null JR Petrie, null A Hughes, null A Jenkins, null H Nickerson, null O Lou, null S Dutta, null Jonathan Haw, null Carol Anderson, null S Kean, null E Thomson, null L Gillespie, null J Gibb, null A Keech, null K March, null S Williams, null E Coady, null M Bots, null B Klein, null J Dreyer, null T Jan, null Koby Sheffy, null Ravit Lusky, null Shlomit Peleg, null J Petrie, null H Colhoun, null A Shore, null D Carty, null P Donnan, null M Witham, null A Adler, null E Lonn, null P Rauchhaus, null R Lindsay, null M Brouwers, null J Van‐Melckebeke, null T Hamill, null L Cuthbertson, null A Murray, null L Jolly, null E Miller, null J Hair, null A Bell, null S Carmichael, null E Douglas, null P Surtees, null E Dinnett, null J Allan, null C Watson, null M McLaughlin, null G Brindley, null E Smillie, null D Motherwell, null S MacDonald, null P Ellis, null D Stuart, null M Travers, null S Brearley, null L Greig, null P Colman, null D West, null S Vaughan, null M Bjorasen, null J Donlan, null J Vrazas, null D O'Neal, null J Horsburgh, null S Kent, null S Twigg, null G Fulcher, null R Denner, null A Piotrowicz, null A Januszewski, null H Pater, null A Coy, null T Paul, null C McDonald, null S Tereschyn, null N Schmidt, null M Weingert, null H Heard, null S Burke, null H Lochnan, null A Sorisky, null E Keely, null J Malcolm, null J Maranger, null C Favreau, null S Petherick, null K Boles, null TW Hansen, null B Hemmingsen, null N Thorogood, null K Green, null T Robinson, null K Abouglilia, null D Nayman, null C Miller, null R Warren, null K Aizawa, null M Balasubramani, null S Toth, null K Harvey, null G Birch, null T Sathyapalan, null A James, null Z Javed, null J Wilding, null B Martin, null S Birch, null A Wilcox, null N Watson, null N Oliver, null N Jugnee, null M Rutter, null T Turgut, null A Shaju, null S Yau, null S Subin, null M Walker, null D Wake, null A Millward, null P Chong, null M Hibbert, null N Schaper, null J Pinxt, null S Philip L Murray, null Linda Sleigh, null K Allan, null J Cook, null K Campbell, null L Hodge, null G Leese, null G Reekie, null K Shields, null A Jaap, null A Sudworth, null A White, null J McKnight, null L Steven, null G McKay, null A Llano, null G Currie, null E Lennon, null J Johnstone, null for the REMOVAL Study Group

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::55b8ba92b6d72b6e2e19fc362141545d
https://doi.org/10.1111/dom.14350/v2/response1

Intravenous minocycline in multidrug-resistant infections: a profile of its use in the USA with a focus on Acinetobacter infections

Autor: Sarah L. Greig, Katherine A. Lyseng-Williamson, Lesley J. Scott

Publikováno v: Drugs & Therapy Perspectives. 33:555-565

Intravenous (IV) minocycline (Minocin®) is approved in the USA for use in patients with infections due to susceptible strains of many bacteria (e.g. Gram-positive and Gram-negative pathogens, including infections due to Acinetobacter spp.). Minocycl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::31f382b9bd665d945ac1f25cd9d45108
https://doi.org/10.1007/s40267-017-0453-3

Pirfenidone in idiopathic pulmonary fibrosis: a guide to its use in the EU

Autor: Katherine A. Lyseng-Williamson, Gillian M. Keating, Sarah L. Greig, Esther S. Kim

Publikováno v: Drugs & Therapy Perspectives. 32:323-329

Pirfenidone (Esbriet®), a synthetic pyridine compound with antifibrotic, anti-inflammatory and antioxidant properties that inhibit the progression of tissue fibrosis, is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). In clinical

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d0e1c9cc7397108d1ff530d2d3d21cfe
https://doi.org/10.1007/s40267-016-0321-6

Carbidopa/levodopa enteral suspension in advanced Parkinson’s disease: a guide to its use

Autor: Sarah L. Greig

Publikováno v: Drugs & Therapy Perspectives. 32:177-185

Carbidopa/levodopa enteral suspension [carbidopa/levodopa ES; Duopa™ (USA); Duodopa® (EU, where it is referred to as intestinal gel)] is indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease (PD). Its de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::042362da2bcadb4491a8e962043b6aa6
https://doi.org/10.1007/s40267-016-0297-2